The use of 18F-FDG PET ratios in the differential diagnosis of common malignant brain tumors



      This study examined the use of positron emission tomography (PET) ratios to improve the diagnostic ability of 18F-FDG PET/computed tomography (CT) in the differentiation of enhancing brain metastases, central nervous system lymphomas, and gliomas.

      Materials and methods

      Seventy-six patients with malignant brain tumors and available magnetic resonance imaging and PET/CT examinations were included.


      Among standardized uptake value (SUV)-related parameters tested, tumor maximum SUV to ipsilateral cortex maximum SUV ratio (Tmax:WMimax) and maximum SUV (SUVmax) proved to be the two most valuable parameters for differential diagnosis.


      In addition to SUVmax, Tmax:WMimax also seems to provide helpful information for the differential diagnosis of lymphomas from other malignant brain tumors.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bulakbasi N
        • Kocaoglu M
        • Ors F
        • Tayfun C
        • Ucoz T
        Combination of single-voxel proton MR spectroscopy and apparent diffusion coefficient calculation in the evaluation of common brain tumors.
        AJNR Am J Neuroradiol. 2003; 24: 225-233
        • Calli C
        • Kitis O
        • Yunten N
        • Yurtseven T
        • Islekel S
        • Akalin T
        Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors.
        Eur J Radiol. 2006; 58: 394-403
        • Kosaka N
        • Tsuchida T
        • Uematsu H
        • Kimura H
        • Okazawa H
        • Itoh H
        18F-FDG PET of common enhancing malignant brain tumors.
        AJR Am J Roentgenol. 2008; 190: W365-W369
        • Barker FG
        • Chang SM
        • Valk PE
        • Pounds TR
        • Prados MD
        18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma.
        Cancer. 1997; 79: 115-126
        • Delbeke D
        • Meyerowitz C
        • Lapidus RL
        • Maciunas RJ
        • Jennings MT
        • Moots PL
        • et al.
        Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET.
        Radiology. 1995; 195: 47-52
        • Palmedo H
        • Urbach H
        • Bender H
        • Schlegel U
        • Schmidt-Wolf IG
        • Matthies A
        • et al.
        FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up.
        Eur J Nucl Med Mol Imaging. 2006; 33: 164-168
        • Charnley N
        • West CM
        • Barnett CM
        • Brock C
        • Bydder GM
        • Glaser M
        • et al.
        Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
        Int J Radiat Oncol Biol Phys. 2006; 66: 331-338
        • Kim YH
        • Oh SW
        • Lim YJ
        • Park CK
        • Lee SH
        • Kang KW
        • et al.
        Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.
        Clin Neurol Neurosurg. 2010; 112: 758-765
        • Dhermain FG
        • Hau P
        • Lanfermann H
        • Jacobs AH
        • van den Bent MJ
        Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas.
        Lancet Neurol. 2010; 9: 906-920
        • Spaeth N
        • Wyss MT
        • Weber B
        • Scheidegger S
        • Lutz A
        • Verwey J
        • et al.
        Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence.
        J Nucl Med. 2004; 45: 1931-1938
        • Tsuyuguchi N
        • Takami T
        • Sunada I
        • Iwai Y
        • Yamanaka K
        • Tanaka K
        • et al.
        Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery in malignant glioma.
        Ann Nucl Med. 2004; 18: 291-296
        • Van Laere K
        • Ceyssens S
        • Van Calenbergh F
        • de Groot T
        • Menten J
        • Flamen P
        • et al.
        Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.
        Eur J Nucl Med Mol Imaging. 2005; 32: 39-51
        • Makino K
        • Hirai T
        • Nakamura H
        • Murakami R
        • Kitajima M
        • Shigematsu Y
        • et al.
        Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.
        Ann Nucl Med. 2011; 25: 432-438
        • Heiss WD
        • Raab P
        • Lanfermann H
        Multimodality assessment of brain tumors and tumor recurrence.
        J Nucl Med. 2011; 52: 1585-1600
        • Benard F
        • Romsa J
        • Hustinx R
        Imaging gliomas with positron emission tomography and single-photon emission computed tomography.
        Semin Nucl Med. 2003; 33: 148-162
        • Hustinx R
        • Smith RJ
        • Benard F
        • Bhatnagar A
        • Alavi A
        Can the standardized uptake value characterize primary brain tumors on FDG-PET?.
        Eur J Nucl Med. 1999; 26: 1501-1509
        • Hamberg LM
        • Hunter GJ
        • Alpert NM
        • Choi NC
        • Babich JW
        • Fischman AJ
        The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?.
        J Nucl Med. 1994; 35: 1308-1312
        • O'Doherty MJ
        • Barrington SF
        • Campbell M
        • Lowe J
        • Bradbeer CS
        PET scanning and the human immunodeficiency virus-positive patient.
        J Nucl Med. 1997; 38: 1575-1583
        • Villringer K
        • Jager H
        • Dichgans M
        • Ziegler S
        • Poppinger J
        • Herz M
        • et al.
        Differential diagnosis of CNS lesions in AIDS patients by FDG-PET.
        J Comput Assist Tomogr. 1995; 19: 532-536
        • Hoffman JM
        • Waskin HA
        • Schifter T
        • Hanson MW
        • Gray L
        • Rosenfeld S
        • et al.
        FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS.
        J Nucl Med. 1993; 34: 567-575
        • Kuwabara Y
        • Ichiya Y
        • Otsuka M
        • Miyake Y
        • Gunasekera R
        • Hasuo K
        • et al.
        High [18F]FDG uptake in primary cerebral lymphoma: a PET study.
        J Comput Assist Tomogr. 1988; 12: 47-48
        • Maza S
        • Buchert R
        • Brenner W
        • Munz DL
        • Thiel E
        • Korfel A
        • et al.
        Brain and whole-body FDG-PET in diagnosis, treatment monitoring and long-term follow-up of primary CNS lymphoma.
        Radiol Oncol. 2013; 47: 103-110
        • Zukotynski K
        • Fahey F
        • Kocak M
        • Kun L
        • Boyett J
        • Fouladi M
        • et al.
        18F-FDG PET and MR imaging associations across a spectrum of pediatric brain tumors: a report from the pediatric brain tumor consortium.
        J Nucl Med. 2014; 55: 1473-1480
        • Rosenfeld SS
        • Hoffman JM
        • Coleman RE
        • Glantz MJ
        • Hanson MW
        • Schold SC
        Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.
        J Nucl Med. 1992; 33: 532-536